Document:

<PAGE>

                                                                   Exhibit 10.9

                      [DATAWARE TECHNOLOGIES LETTERHEAD]

                                                         November 15, 1999

Robert J. Farrell
123 Edgewood Avenue
Smithtown, NY  11787

Dear Bob:

I am very pleased to confirm our offer to you to join Dataware Technologies,
Inc. as Executive Vice President of Worldwide Field Operations, Chief Operating
Officer reporting to Dave Mahoney, the President and Chief Executive Officer.

The terms of our offer of employment are summarized in the attached Proposed
Employment Terms.

In order to accept this position, please sign a copy of this letter and return
it to me.  Retain a copy for your records.

We are looking forward to working with you at Dataware.

Best Regards,

DATAWARE TECHNOLOGIES, INC.

 /s/ Ann Smith

Ann Smith
Vice President Corporate Resources

Offer Accepted:

By    /s/ Robert J. Farrell          Date  11/19/99
      ---------------------                --------

Enclosure

AS:jag
<PAGE>

                                Robert Farrell
                               Employment Terms

Position:     Executive Vice President of Field Operations, Chief Operating
--------      Officer reporting to the Chief Executive Officer.

Term:         Your employment will commence on a date to be determined following
----          your acceptance of the offer (the "Start Date"). Employment with
              Dataware can be terminated at any time at the option of either you
              or the Company.

Base Salary:  $250,000 per year, payable semi-monthly.
------------

Bonus:        $100,000 annual bonus opportunity (beginning with FY 2000) based
-----         on the achievement of Company revenue and earning performance
              targets. Fifty percent (50%) of the annual bonus opportunity,
              $50,000, is guaranteed subject to continued employment for the
              first 6 months of 2000. This bonus will be paid quarterly at the
              rate of at $12,500 per quarter for 4 quarters. Any remaining
              portion of the annual bonus opportunity will be earned based on
              the Company achieving its earnings and revenue targets and will be
              payable following the end of the year.

Benefits:     You will be entitled to medical, dental, disability, and life
--------      insurance, 15 days paid vacation, 5 paid personal days and 5 paid
              sick days (accruing in proportion to the time worked during a
              calendar year) and 10 paid holidays per calendar year and other
              benefits provided to our executive employees.

              In addition, you will be eligible for $750,000 of company paid
              term life insurance.

Relocation:   You will be reimbursed for reasonable expenses of relocating your
----------    family and household to the Boston area. The company would prefer
              that your relocation be completed within 12 months of your date of
              employment. If your relocation is completed within your first 12
              months of employment, you will be granted an additional 15,000
              shares of ISO options. These options will be priced according to
              the provisions outlined in the equity section below. These options
              will vest immediately upon the completion of your relocation
              provided it occurs no later than 12 months from your date of
              employment.

              The Company will provide temporary living accommodations for you
              at no expense to you for a period not to exceed 12 months.

Expenses:     The Company will reimburse you for reasonable business related
--------      expenses, including travel in accordance with the Company travel
              policy. Since your permanent office will be at the Cambridge
              headquarters, weekly travel between your home and your office will
              be considered business travel and will be reimbursed. Mileage
              reimbursements for business-related travel by private car will be
              at the latest IRS approved rate.

Equity:       The Company will grant you a qualified (ISO) stock option for
------        150,000 shares, subject to approval by the Dataware Board of
              Directors. The exercise price will
<PAGE>

              be the fair market value on the grant date, defined as the closing
              price on the day before the grant is issued.

              As part of this offer, options on the first 37,500 shares will
              vest on December 31, 1999. If you exercise these vested options,
              the Company will hold the certificate for the shares until you
              relocate your family and household to the Boston area. In the
              event that your employment is terminated within the first 12
              months and you have not relocated to the Boston area by then, the
              shares will be forfeited to the Company in exchange for repayment
              of the exercise price.

              The remaining options will vest at the rate of 37,500 per year
              annually on December 31. Vesting will be accelerated upon a
              "Change in Control" of the Company, as defined in the Company's
              Equity Incentive Plan. .

              Should there be a "Change in Control" of the Company, as defined
              in the Company's Equity Incentive Plan, and you are not offered an
              equivalent position at or above your then current compensation,
              vesting will be accelerated.

Severance:    Should the Company terminate you without "Cause" or should there
---------     be a Change in Control of the Company and, as a result, your
              employment with the Company is terminated, the Company will
              continue your base salary plus earned pro-rata bonus for a period
              of six (6) months, plus one additional month for each full year of
              service with the Company. Total severance will be limited to
              twelve (12) months-base salary plus earned pro-rata bonus.
              Severance payments will be reduced by any amounts you receive from
              subsequent employment during the severance period.

              For this purpose, "Cause" means (i) your commission of a felony;
              (ii) your continued failure (other than any such failure resulting
              from your incapacity due to physical or mental illness) to perform
              your duties with the Company after the Company has delivered
              written notice of such failure; (iii) your falsification of any
              records, documents or systems of the Company or any other conduct
              that is materially harmful to the Company or any of its customers
              or suppliers; or (iv) your violation of any material provision of
              any confidentiality, assignment of invention, noncompetition or
              similar agreement with the Company.

Other:        You will need to sign non-disclosure and non-competition
-----         agreements satisfactory to the Company prior to your start date.
              You will also need to certify that you have no outstanding non-
              disclosure, non-compete or employment obligations that would
              interfere with your full-time employment by Dataware.

Offer Accepted:

By   /s/ Robert  J. Farrell             Date  11/19/99
     ---------------------------              -----------------

Start Date:   TBD
            --------<PAGE>

                                                                    EXHIBIT 10.7

                                    CREATIVE
                          IRREVOCABLE LICENSE AGREEMENT

     This Agreement, dated November 20, 1998 by and between Creative
BioMolecules, Inc., a Delaware corporation with its principal office at 35 South
Street, Hopkinton, Massachusetts 01748 ("CBM") and Stryker Corporation, a
Michigan corporation with its corporate office at 2725 Fairfield Road, P.O. Box
4085, Kalamazoo, Michigan 49003-4085 ("Stryker").

     WHEREAS, the patents and patent applications listed on Schedule 1 attached
hereto have been assigned to Stryker by CBM; and

     WHEREAS, it is the intention of Stryker, by this Irrevocable License
Agreement, to grant to CBM an exclusive license under the Assigned Patent
Rights, subject, however, to the exclusive rights of Stryker in the Stryker
Field (as such terms are defined herein);

     NOW, THEREFORE, in consideration of the foregoing, and of the assignment of
the Assigned Patent Rights by CBM to Stryker, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties, intending to be legally bound, hereby agree as follows:

     1.   Definitions. As used herein, the following words shall have the
          -----------
following meanings:

          a. "Assigned Patent Rights" shall mean (i) the patents and patent
     applications listed on Schedule 1 attached hereto, (ii) any patent
     applications and patents deemed to be Assigned Patents pursuant to Section
     4.2 of the Master Agreement, and (iii) all worldwide counterparts and
     registrations, continuations, divisions, reissues, extensions or
     supplementary protection certificates, continuations-in-part or additions
     (but only to the extent such continuations-in-part or additions claim
     inventions disclosed as required by 35 U.S.C. (S)112 (CIPs) or the
     applicable laws (additions) in the parent application therefor listed in
     Schedule 1) with respect thereto, and all patents issuing therefrom.
<PAGE>

          b. "Biological Materials" shall mean any biological materials, assays,
     substances or reagents, including without limitation transformed or
     transfected cells (including any cell expressing an OP Product or any
     analog, mutation or heterodimer thereof), cell lines, DNA sequences,
     vectors, host cells, proteins, antibodies and any fragments or subcellular
     components thereof.

          c.  "Bone Diseases" shall mean Osteoporosis, Osteomalacia and Paget's
     Disease.

          d. "OP" shall mean proteins (or the active sites thereof) or
     polypeptides or combinations of proteins and polypeptides which produce an
     osteogenic effect.

          e. "OP Products" shall mean OP and polyclonal or monoclonal antibodies
     of OP and specific inhibitors or inhibitory activities of the osteogenic
     effect of OP, which inhibitors or inhibitory activities are found and
     identified as such in the course of the Research Project (as defined in the
     Second Amended and Restated Research, Development and Supply Agreement,
     dated May 17, 1991, between CBM and Stryker, as amended).

          f.  "OP Devices" shall mean the combination of OP Products with
     suitably biocompatible and biodegradable carriers.

          g. "Bone Disease Field" shall mean the prevention or treatment of the
     Bone Diseases other than (i) by the local application of OP Products and OP
     Devices in an insoluble formulation directly on bone or joint tissue for
     local, as opposed to general or systemic, effect and (ii) the treatment of
     fractures regardless of whether they result from a Bone Disease.

          h. "Stryker Manufacturing Know-How" means all inventions, know-how,
     Biological Materials, designs, trade secrets, copyrights, processes,
     formulas, techniques, discoveries, ideas and the like that, as of the
     Closing Date (as defined in the Master Agreement), are owned by Stryker or
     as to which Stryker has acquired rights which are

                                       2
<PAGE>

     licensable hereunder, that are necessary or useful in the manufacture of OP
     Products or OP Devices.

          i. "Stryker Field" shall mean the field of (i) treatment, repair or
     replacement of bone and joint tissue, including, without limitation,
     meniscus and articular cartilage and ligaments and tendons, but excluding
     the Bone Disease Field, and (ii) treatment, repair or replacement of the
     tooth, dentin, alveolar bone, cementum, enamel, gingiva (to the extent, but
     only to the extent, the gingiva functions as part of the apparatus holding
     the tooth to the jaw) and/or periodontal ligament, but excluding the
     treatment of Oral Ulcerations (as defined below) or any other disease or
     disorder of the tissues of the mouth not involving the tooth, dentin, bone
     (including alveolar bone), cementum, enamel, gingiva (to the extent, but
     only to the extent, the gingiva functions as part of the apparatus holding
     the tooth to the jaw), ligament (including the periodontal ligament),
     tendon and/or cartilage.

          As used herein, "Oral Ulcerations" means the formation of lesions on
     the surface of skin lining the oral cavity caused by loss of tissue but
     does not include Periodontal Disease (as defined below) or any other
     disease or disorder involving the tooth, dentin, bone (including alveolar
     bone), cementum, enamel, gingiva (to the extent, but only to the extent,
     the gingiva functions as part of the apparatus holding the tooth to the
     jaw), ligament (including the periodontal ligament), tendon and/or
     cartilage.

          As used herein, "Periodontal Disease" means degeneration of the
     apparatus holding the tooth to the jaw involving damage to any or all of
     the gingiva (to the extent, but only to the extent, the gingiva functions
     as part of the apparatus holding the tooth to the jaw), alveolar bone,
     cementum, enamel and periodontal ligament.

          j.  "Creative Field" means all uses and applications other than the
     Stryker Field.  The Creative Field includes, without limitation, the Bone
     Disease Field.

                                       3
<PAGE>

          k.  "Master Agreement" means the Master Restructuring Agreement dated
     October 15, 1998 between Stryker and CBM.

     2. Grant of Exclusive License. Stryker hereby grants to CBM an irrevocable,
        --------------------------
exclusive, worldwide license, with the unrestricted right to grant sublicenses,
to all of the Assigned Patent Rights for all uses and applications of all
inventions claimed therein, except for the manufacture, use, importation and
sale of OP Products and OP Devices for use in the Stryker Field, which grant
shall be exclusive even as to Stryker, with respect to the Creative Field, it
being understood that Stryker retains the exclusive right to manufacture, use,
import and sell OP Products and OP Devices for use in the Stryker Field. Such
license shall not be terminable by Stryker or any successor, assign or any party
claiming through Stryker under any circumstances or for any reason (including,
without limitation, any breach or default under any other agreement between
Stryker and CBM).

     3. Grant of Non-Exclusive License. Stryker hereby grants to CBM an
        ------------------------------
irrevocable, non-exclusive, worldwide license, with the unrestricted right to
grant sublicenses under all Stryker Manufacturing Know-How solely for use (a) in
the manufacture of OP, OP Products or products or devices formulated with OP for
use in the Creative Field, and (b) in the manufacture of proteins or
polypeptides (or combinations of proteins or polypeptides) other than OP.

     4. Retained Rights. Notwithstanding Section 2, Stryker hereby retains for
        ---------------
itself the right to use OP Products and OP Devices as research and development
tools for the development of other products and devices for use in the Stryker
Field. Nothing in the license granted to Creative hereunder shall preclude
Stryker from engaging in the development, production and sale of products and
devices in the Stryker Field.

     5.   Recording of License. Stryker shall record this license in the United
          --------------------
States Patent and Trademark Office and such other foreign patent offices as CBM
shall determine to be appropriate.

                                       4
<PAGE>

     6.   Miscellaneous.
          -------------
          a. This Agreement may only be amended by a written instrument signed
     by both parties, which makes specific reference to this Agreement.

          b. CBM may assign this Agreement without the consent of Stryker. This
     Agreement shall be binding upon and shall inure to the benefit of CBM and
     Stryker and their respective successors and assigns.

          c.  This Agreement is governed by the laws of the State of Delaware.

          d.  This Agreement shall supersede the Irrevocable License Agreement
     dated May 17, 1991 between Stryker and CBM.

     IN WITNESS WHEREOF, the parties have executed this Agreement under seal as
of the date first above written.

CREATIVE BIOMOLECULES, INC.              STRYKER CORPORATION

By: /s/ Michael M. Tarnow                By:  /s/ REK
    ----------------------------              ---------------------------
Title:  President and CEO                Title: Assistant Secretary
        ------------------------                -------------------------

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]